Peritoneal Cancer Study
GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC# 704865, IND# 7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurren
Protocol ID
Protocol Description
This study is being done to find a more effective treatment for ovarian, fallopian tube or peritoneal primary cancer that has come back after a patient's original treatment. One purpose of this study is to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone.
Effectiveness of treatment will be measured in terms of survival, time without evidence of cancer growth and quality of life (wellness and physical functioning).
A second purpose of this study is to determine if a second surgery to remove tumors followed by chemotherapy can increase the time that patients remain disease free.
Eligibility Criteria
Women whose ovarian, fallopian tube or peritoneal primary cancer has returned after original treatment
Primary Investigator(s)
- Veena John, MD